Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07351747

Effect of Laser Acupoints on Fallopian Tube Obstruction

This study aims to determine the efficacy of laser acupoint therapy on treating fallopian tube obstruction.

Recruiting

Interested in participating?

Request Info

Key information

Age range

20 year–35 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Kafrelsheikh University (Faculty of Physical Therapy)

Kafr ash Shaykh, Kafrelsheikh, 33516, Egypt

Location status: Recruiting

Location contact

Fayiz F Elshamy, MD

SUB_INVESTIGATOR

Hadeer E Shalaby, MBBCH

CONTACT

[email protected]

00201554488336

Mostafa F Ellkany, MD

SUB_INVESTIGATOR

About this study

Fallopian tube obstruction is a significant health concern that affects a substantial number of women worldwide, often leading to infertility and other reproductive issues. The fallopian tubes, essential components of the female reproductive system, play a crucial role in the process of conception by facilitating the transport of ova from the ovaries to the uterus.

The laser's focused light energy, when directed at specific acupoints linked to reproductive health, is hypothesized to activate the body's energy pathways or meridians, thereby facilitating healing and restoration of normal tubal function.

Although acupoint therapy shows promise, laser acupoint therapy offers potential advantages over traditional acupuncture by utilizing low-level lasers, which may enhance the treatment's efficacy. Laser acupoint therapy is noninvasive and painless, making it articularly appealing for patients who have a fear of needles or are sensitive to pain.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Women aged 20-35 years - nulliparous.
  • Women diagnosed with fallopian tube obstruction.
  • Body mass index less than 30 kg/m2.
  • Consent to participate in the study.
  • General good health with no major co-existing medical conditions that could interfere with the treatment or outcomes.
  • No prior fertility treatments [e.g., In vitro fertilization (IVF), intrauterine insemination (IUI)] within the last 6 months.
  • Ability to attend all scheduled sessions and follow-up assessments.

Exclusion criteria

  • Currently pregnant or breastfeeding.
  • History of pelvic surgery within the past year.
  • Presence of severe systemic diseases such as active cancer or severe cardiovascular diseases.
  • History of allergic reactions or adverse responses to acupuncture or laser therapies.
  • Currently undergoing hormonal therapy or use of hormonal contraceptives.
  • Current or recent history of genital tract infections, including sexually transmitted. infections, which could affect the reproductive system.
  • Presence of significant uterine anomalies diagnosed through imaging that could impact fertility.
  • Polycystic Ovary Syndrome (PCOS).

Treatment and study plan

Laser acupoints therapy + Standard care

Other

Patients will receive laser acupoints therapy addition to standard care.

Standard care

Other

Patients will receive placebo laser acupoints therapy in addition to standard care.

Primary outcomes

  1. Tubal patency

    Time frame: 3 months post-treatment

    Hysterosalpingography (HSG) will be used to assess tubal patency. It is a radiographic technique where a contrast material is injected into the uterine cavity, and X-ray images are taken to evaluate the shape of the uterus and the status of the fallopian tubes. HSG will be applied before the treatment and again three months post-treatment to evaluate changes in tubal patency HSG will be applied before treatment and after 3 months post-treatment.

Secondary outcomes

  1. Anti-Müllerian Hormone (AMH) Test

    Time frame: 3 months post-treatment

    A blood test will be used to measure the level of Anti-Müllerian Hormone (AMH), which is an indicator of the remaining quantity of eggs and ovarian function. This test will be conducted before the treatment and at the third month of treatment to monitor any changes in ovarian reserve.

  2. Quantitative Pregnancy Test

    Time frame: 3 months post-treatment

    A blood test that will be measured the specific level of Human Chorionic Gonadotropin (hCG), which is produced during pregnancy. This test will be performed every month.

Study contacts

Contact information is provided by the study sponsor or research team.

Hadeer E Shalaby, MBBCH

CONTACT

[email protected]

00201554488336

Sponsors and collaborators

Lead sponsor

Kafrelsheikh University

Other

Registry information

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Jan 20, 2026
Registry last updated
Jan 20, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.